Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-aminolevulinic acid hydrochloride + sodium ferrous citrate
- Development stage
- Phase 2
- Lead developer
- SBI Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**5-aminolevulinic acid hydrochloride + sodium ferrous citrate** is an oral combination of a heme biosynthesis precursor (5-aminolevulinic acid, or 5-ALA) and an iron supplement (sodium ferrous citrate, SFC). The combination enhances mitochondrial function, induces heme oxygenase-1 (HO-1), activates antioxidative pathways, and modulates cellular metabolism. The drug has been researched for a variety of indications, including Leigh syndrome, muscle function decline, renal protection during chemotherapy, obesity, diabetes, and as a therapeutic supplement in COVID-19. Several studies emphasize its mitochondrial activation, anti-inflammatory, and potential antiviral effects. The combination is sometimes designated by the codes SPP-003 (in oncology/renal protection) and SPP-004 (in Leigh syndrome/mitochondrial disorders)[1][7][9].
- Brand names
- SPP-003SPP003SPP 003SPP-004SPP004SPP 004
- Other names
- 5-aminolevulinic acid + sodium ferrous citrateaminolevulinic acid/sodium ferrous citratesodium ferrous citrate/aminolevulinic acid
02
Targets
FECH (Ferrochelatase)HMOX1 (Heme oxygenase 1)
Beyond the preview
Go deeper on 5-aminolevulinic acid hydrochloride + sodium ferrous citrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-aminolevulinic acid hydrochloride + sodium ferrous citrate.